Literature DB >> 8433635

Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.

M Krahn1, A S Detsky.   

Abstract

This paper examines the economic attractiveness of universal vaccination of infants with hepatitis B virus (HBV) vaccine by calculating the incremental cost-effectiveness of this strategy when compared with the currently recommended strategy of screening all pregnant women and vaccinating only infants born to HBsAg+ mothers. A decision-analytic model involving a Markov process to model the long-term sequelae of HBV infection was constructed to estimate the expected costs and life expectancies for a cohort of newborns under two strategies: the current screening policy (SELECTIVE), which involves active and passive vaccination of infants born to carrier mothers, and a policy that combines the current screening strategy (including active and passive vaccination of infants born to carriers) with active vaccination alone for children of non-carriers (UNIVERSAL). A hypothetical cohort of children born in either Canada or the United States in 1991 was examined. Cost estimates were derived for Ontario. From a societal perspective, the incremental cost required to achieve one extra life year was found to be $30,347, comparable to the cost-effectiveness of other health care strategies commonly used in North America. The result is sensitive to the duration of vaccine effectiveness and particularly to the price of the vaccine. Universal vaccination results in net cost saving at a vaccine price of approximately $7 per dose, from a societal perspective. It is concluded that universal vaccination against HBV in infancy is economically attractive, comparable in cost-effectiveness to existing health care interventions. Lower vaccine prices would substantially improve the attractiveness of such a program. Implementation of universal vaccination should be considered in North America, contingent on vaccine price reduction. A monitoring program to ensure the long-term efficacy of the vaccine should be part of such a program.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8433635     DOI: 10.1177/0272989X9301300103

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  12 in total

1.  Costs in Perspective: Understanding Cost-Effectiveness Analysis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  Effectiveness and cost comparison of two strategies for hepatitis B vaccination of schoolchildren.

Authors:  Maryse Guay; Anne-Marie Clouâtre; Manon Blackburn; Geneviève Baron; Philippe De Wals; Chantale Roy; Jean Desrochers; François Milord
Journal:  Can J Public Health       Date:  2003 Jan-Feb

3.  Cost effectiveness of hepatitis B immunisation strategies.

Authors:  A L Hillman; I Blasco; B S Bloom; J S Schwartz
Journal:  Pharmacoeconomics       Date:  1994-02       Impact factor: 4.981

4.  Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.

Authors:  A S Detsky
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 5.  Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection.

Authors:  S M Holliday; D Faulds
Journal:  Pharmacoeconomics       Date:  1994-02       Impact factor: 4.981

6.  Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain.

Authors:  F Antoñanzas; R Garuz; J Rovira; F Antón; C Trinxet; E Navas; L Salleras
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

7.  RECOMMENDATION FOR HEPATITIS - B VACCINATION.

Authors:  A Bahadur; S K Dham
Journal:  Med J Armed Forces India       Date:  2017-06-27

8.  Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment.

Authors:  Solomon Chih-Cheng Chen; Mehlika Toy; Jennifer M Yeh; Jung-Der Wang; Stephen Resch
Journal:  Pediatrics       Date:  2013-03-25       Impact factor: 7.124

9.  Medical decision analysis in infectious diseases.

Authors:  U D Allen
Journal:  Can J Infect Dis       Date:  2000-11

10.  Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program.

Authors:  M Krahn; R Guasparini; M Sherman; A S Detsky
Journal:  Am J Public Health       Date:  1998-11       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.